Apeiron Biologics has approval to conduct a Phase II clinical trial of APN01 (human recombinant ACE2) for the treatment of COVID‐19 in three European countries (Austria, Germany and Denmark) (NCT04335136). Here, ACE2 is linked to COVID-19.